Plain-English translation of NCT06941363 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This clinical trial is testing a new approach called salvage ultrahypofractionated radiotherapy — a specialized radiation treatment delivered in a single, powerful dose to the area where your prostate was removed. The study is designed for men whose prostate cancer markers (PSA levels) have returned or remained detectable after prostate surgery, but who have no signs of cancer spread to other parts of the body. Researchers want to learn whether this single-dose treatment is safe and how many side effects occur.
After prostate surgery, some men develop rising PSA levels indicating cancer recurrence in the surgical area. This new treatment aims to offer a faster, more convenient alternative to traditional multi-week radiation therapy, while carefully monitoring safety to find the best dose.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive a single radiation treatment delivered using advanced imaging guidance to target the prostate bed precisely. The study is conducted in two stages: first, researchers will test three different dose levels in small groups of patients to find the safest dose, then expand to enroll more patients at that dose level. You will be monitored closely for 90 days after treatment to check for any side effects, and you may be asked to complete questionnaires about your health and symptoms.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy